Synapse Open Synapse
Patents & IP

AI-enabled medical devices require an integrated FDA and IP strategy following draft guidance on pre-market submissions

IAM · · 2 min read

Following the publication of an FDA discussion paper and draft guidance, medical device companies should prepare a cohesive patent and pre-market submission strategy by considering FDA recommendations when developing AI-enabled features and coordinating statements made to the USPTO and the FDA.

Latest from IAM